Historical Information

Provided by: Senhwa Biosciences, Inc.

SEQ_NO	1	Date of announcement	2024/11/06	Time of announcement	06:30:57

Subject: Senhwa announces first patient enrolled in the Phase I/II study of Silmitasertib in children and young adults with relapsed refractory solid tumors.

Date of events: 2024/11/06 To which item it meets: paragraph 53

Statement:

1.Date of occurrence of the event:2024/11/06
2.Company name:Senhwa Biosciences Inc.
3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Headquarter
4.Reciprocal shareholding ratios:Not applicable
5.Cause of occurrence:
(1)The Company announced the enrollment of the first patient at Penn State Health Children’s Hospital in its Phase I/II clinical study evaluating the efficacy of Silmitasertib (CX-4945) in combination with chemotherapy for children and young adults with relapsed or refractory solid tumors. For details regarding the approval, trial objectives, and planning of this study, please refer to our company's material information announced dated August 6, 2024.
(2)The Phase I/II human trial is led by the internationally renowned pediatric hematologist/oncologist, Dr. Giselle Saulnier Sholler. In August 2023, Dr. Sholler was invited to serve as the division chief of Pediatric Hematology and Oncology at Penn State Health Children’s Hospital and the director of pediatric oncology research at Penn State College of Medicine. She is also the chair and founder of the Beat Childhood Cancer Research Consortium, which has enrolled 1,800 pediatric oncology patients across 23 clinical trials. Notably, this Consortium has successfully contributed to the development of a New Drug Application for the prevention of relapse in high-risk neuroblastoma, leading to its FDA approval. Our company looks forward to this collaborative project with great anticipation.
(3)A single clinical trial result does not reflect the success or failure of new drug development and launch in the future. Investors should make prudent judgments and investments.
6.Countermeasures:Upload the material information on Market Observation Post System.
7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):None. Drug development requires huge amount of time and investment, and there is no guarantee of success, which may put the investment at risk. Investors should make prudent judgments on investments.